The analyst's Medical Devices sector report, “Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Dry Powder Inhaler Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to :
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
2 Introduction
3 Products under Development
4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies
7 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1nhaler Ltd
- Acorda Therapeutics Inc
- Advent Pharmaceuticals Pty Ltd
- Aespira Ltd.
- AKELA Pharma Inc. (Formerly LAB International, Inc.) (Inactive)
- Bayer AG
- Belhaven Biopharma Inc
- Cambridge Healthcare Innovations Ltd
- Creare LLC
- DMK Pharmaceuticals Corp
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Hovione Technology Ltd
- Iconovo AB
- Lupin Pharmaceuticals Inc
- MannKind Corp
- Monash University
- Nektar Therapeutics
- Ology Bioservices Inc
- OPKO Health Inc
- OtiTopic Inc
- Phargentis SA
- PureIMS BV
- Quench Medical Inc
- Receptor Life Sciences Inc
- Respira Therapeutics Inc
- Respirent Pharmaceuticals Co Ltd
- Sandoz International GmbH
- Sheffield Hallam University
- Shin Nippon Biomedical Laboratories Ltd
- Spyryx Biosciences Inc (Inactive)
- Syntara Ltd
- Teva Pharmaceutical Industries Ltd
- Transpire Bio Inc
- United Therapeutics Corp
- University of Kansas
- University of Sydney
- University of Texas Medical Branch at Galveston
- Vectura Group Plc
- Verona Pharma Plc
- Virginia Commonwealth University